On March 1, 2022 Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "ONO") reported that it has filed a lawsuit for an injunction and damages (value of the subject matter of the suit is about 32 billion yen) against patent infringement, based on the patent on the anti-PD-L1 antibody owned by ONO (JP5885764; JP6258428), to the Tokyo District Court on February 28 against AstraZeneca K.K., which has been marketing Imfinzi (durvalumab) (Press release, Ono, MAR 1, 2022, View Source [SID1234609346]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

　ONO is a research and development company that creates world-class, innovative new drugs under the corporate philosophy, "Dedicated to the Fight against Disease and Pain." We recognize intellectual property as an extremely important management asset. Therefore, we have decided to take appropriate measures against acts that infringe our intellectual property rights, leading to the filing of such a lawsuit this time.

　Considering that the treatment is related to the life-saving of patients, we will not ask for a sales injunction of Imfinzi in this lawsuit, if we would make an agreement with AstraZeneca K.K. which will pay to ONO an appropriate consideration including royalties even outside the proceedings.